Henri Termeer joins Prosensa as Strategic Advisor

Leiden, The Netherlands – 13 December 2012 – Prosensa, the Dutch bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on RNA-mod­u­lat­ing ther­a­peu­tics for rare dis­eases with high unmet need, has appoint­ed indus­try leader and for­mer Genzyme CEO, Mr. Henri Termeer as Strategic Advisor. His role at Prosensa will be to pro­vide input on the company’s cor­po­rate strat­e­gy and growth plans.
Commenting on his appoint­ment, Mr. Termeer said: “Prosensa has the key ingre­di­ents of a suc­cess­ful com­pa­ny in the rare dis­ease com­mu­ni­ty: break­through sci­ence, a high­ly moti­vat­ed work­force and a pas­sion­ate com­mit­ment to improv­ing the lives of patients. I am very much look­ing for­ward to work­ing with the Prosensa team.”
Prosensa’s CEO, Hans Schikan, com­ment­ed: “We are very pleased that Henri is join­ing the team as a Strategic Advisor. Under his lead­er­ship, Genzyme became a world-lead­ing biotech com­pa­ny and a pio­neer in rare dis­eases and orphan drugs. His exper­tise will be invalu­able to use as we dri­ve our prod­ucts and tech­nol­o­gy for­ward.”
Henri Termeer served as Chairman, President and CEO of Genzyme Corporation for near­ly three decades. Under his lead­er­ship, the com­pa­ny evolved from a mid-sized bio­med­ical com­pa­ny to one of the world’s lead­ing bio­phar­ma­ceu­ti­cal com­pa­nies, espe­cial­ly in the field of rare dis­eases and orphan drugs. He retired from Genzyme in 2011 fol­low­ing its acqui­si­tion by Sanofi in a trans­ac­tion val­ued at more than $20 bil­lion. Mr. Termer is also involved in a num­ber of oth­er com­pa­nies and not-for-prof­it orga­ni­za­tions.
Commenting on the appoint­ment, Mr. Daan Ellens, Chairman of Prosensa’s Supervisory Board, said: “Henri is a lumi­nary in the biotech world, and an expert in rare dis­eases and orphan drugs. His exper­tise will be cru­cial in sup­port­ing our goal of devel­op­ing and com­mer­cial­is­ing oligonu­cleotide treat­ments for rare neu­ro­mus­cu­lar dis­or­ders. We wel­come him on board.”

Leave a Reply

Your email address will not be published. Required fields are marked *